High plateletcrit may be associated with thrombotic risk in polycythemia vera

Ivan Krečak^{1

2}, Ivan Zekanović³, Martina Morić Perić³, Hrvoje Holik^{4

5}, Božena Coha⁴, Vlatka Periša^{5

6}, Marko Lucijanić^{7

8}

Affiliations

¹ Department of Internal Medicine, General Hospital of Šibenik-Knin County, Šibenik, Croatia.
² Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
³ Department of Internal Medicine, General Hospital Zadar, Zadar, Croatia.
⁴ Department of Internal Medicine, Dr. Josip Benčević General Hospital, Slavonski Brod, Croatia.
⁵ School of Medicine, University of Osijek, Osijek, Croatia.
⁶ Division of Hematology, University Hospital Osijek, Osijek, Croatia.
⁷ Division of Hematology, University Hospital Dubrava, Zagreb, Croatia.
⁸ School of Medicine, University of Zagreb, Zagreb, Croatia.

Comment

Ivan Krečak et al. Int J Lab Hematol. 2023 Oct.

. 2023 Oct;45(5):799-801.

doi: 10.1111/ijlh.14073. Epub 2023 Apr 12.

Ivan Krečak^{1

2}, Ivan Zekanović³, Martina Morić Perić³, Hrvoje Holik^{4

5}, Božena Coha⁴, Vlatka Periša^{5

6}, Marko Lucijanić^{7

8}

¹ Department of Internal Medicine, General Hospital of Šibenik-Knin County, Šibenik, Croatia.
² Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
³ Department of Internal Medicine, General Hospital Zadar, Zadar, Croatia.
⁴ Department of Internal Medicine, Dr. Josip Benčević General Hospital, Slavonski Brod, Croatia.
⁵ School of Medicine, University of Osijek, Osijek, Croatia.
⁶ Division of Hematology, University Hospital Osijek, Osijek, Croatia.
⁷ Division of Hematology, University Hospital Dubrava, Zagreb, Croatia.
⁸ School of Medicine, University of Zagreb, Zagreb, Croatia.

No abstract available

Comment on

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia.
Rocca B, Tosetto A, Betti S, Soldati D, Petrucci G, Rossi E, Timillero A, Cavalca V, Porro B, Iurlo A, Cattaneo D, Bucelli C, Dragani A, Di Ianni M, Ranalli P, Palandri F, Vianelli N, Beggiato E, Lanzarone G, Ruggeri M, Carli G, Elli EM, Carpenedo M, Randi ML, Bertozzi I, Paoli C, Specchia G, Ricco A, Vannucchi AM, Rodeghiero F, Patrono C, De Stefano V. Rocca B, et al. Blood. 2020 Jul 9;136(2):171-182. doi: 10.1182/blood.2019004596. Blood. 2020. PMID: 32266380 Clinical Trial.

1. Krecak I, Lucijanic M, Verstovsek S. Advances in risk stratification and treatment of polycythemia vera and essential thrombocythemia. Curr Hematol Malig Rep. 2022;17(5):155-169.
1. McMullin MF, Harrison CN, Ali S, et al. A British Society for Haematology guideline. Br J Haematol. 2019;184(2):176-191.
1. Patrono C, Rocca B, De Stefano V. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood. 2013;121(10):1701-1711.
1. Cervantes F, Arellano-Rodrigo E, Alvarez-Larrán A. Blood cell activation in myeloproliferative neoplasms. Haematologica. 2009;94(11):1484-1488.
1. Di Nisio M, Barbui T, Di Gennaro L, et al. European collaboration on low-dose aspirin in polycythemia vera (ECLAP) investigators. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136(2):249-259.